{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T02:24:52Z","timestamp":1794104692726,"version":"4.8.0"},"reference-count":69,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,7,1]]},"abstract":"<jats:p>Natural killer (NK) cells hold promise for improving the therapeutic potential of allogeneic hematopoietic transplantation, but their effectiveness is limited by inhibitory HLA types. We sought to overcome this intrinsic resistance by transducing CD56+CD3- NK cells with chimeric receptors directed against CD19, a molecule widely expressed by malignant B cells. An abundance of NK cells for transduction was secured by culturing peripheral blood mononuclear cells with K562 cells expressing the NK-stimulatory molecules 4-1BB ligand and interleukin 15, which yielded a median greater than 1000-fold expansion of CD56+CD3- cells at 3 weeks of culture, without T-lymphocyte expansion. Expression of anti-CD19 receptors linked to CD3\u03b6 overcame NK resistance and markedly enhanced NK-cell-mediated killing of leukemic cells. This result was significantly improved by adding the 4-1BB costimulatory molecule to the chimeric anti-CD19-CD3\u03b6 receptor; the cytotoxicity produced by NK cells expressing this construct uniformly exceeded that of NK cells whose signaling receptors lacked 4-1BB, even when natural cytotoxicity was apparent. Addition of 4-1BB was also associated with increased cell activation and production of interferon \u03b3 and granulocyte-macrophage colony-stimulating factor. Our findings indicate that enforced expression of signaling receptors by NK cells might circumvent inhibitory signals, providing a novel means to enhance the effectiveness of allogeneic stem cell transplantation.<\/jats:p>","DOI":"10.1182\/blood-2004-12-4797","type":"journal-article","created":{"date-parts":[[2005,3,8]],"date-time":"2005-03-08T22:43:46Z","timestamp":1110321826000},"page":"376-383","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":591,"title":["Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells"],"prefix":"10.1182","volume":"106","author":[{"given":"Chihaya","family":"Imai","sequence":"first","affiliation":[{"name":"From the Departments of Hematology-Oncology and Pathology, St Jude Children's Research Hospital, Memphis; and Department of Pediatrics, University of Tennessee College of Medicine, Memphis."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology-Oncology and Pathology, St Jude Children's Research Hospital, Memphis; and Department of Pediatrics, University of Tennessee College of Medicine, Memphis."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Campana","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology-Oncology and Pathology, St Jude Children's Research Hospital, Memphis; and Department of Pediatrics, University of Tennessee College of Medicine, Memphis."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021223230224600_REF1","doi-asserted-by":"crossref","unstructured":"Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukemia\u2014current status and future perspectives. Lancet Oncol. 2001;2: 597-607.","DOI":"10.1016\/S1470-2045(01)00516-2"},{"key":"2020021223230224600_REF2","doi-asserted-by":"crossref","unstructured":"Champlin R. T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation. Hematol Oncol Clin North Am. 1990;4: 687-698.","DOI":"10.1016\/S0889-8588(18)30486-6"},{"key":"2020021223230224600_","doi-asserted-by":"crossref","unstructured":"Porter DL, Antin JH. The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med. 1999;50: 369-386.","DOI":"10.1146\/annurev.med.50.1.369"},{"key":"2020021223230224600_REF4","doi-asserted-by":"crossref","unstructured":"Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411: 385-389.","DOI":"10.1038\/35077251"},{"key":"2020021223230224600_REF5","doi-asserted-by":"crossref","unstructured":"Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994;330: 100-106.","DOI":"10.1056\/NEJM199401133300204"},{"key":"2020021223230224600_REF6","doi-asserted-by":"crossref","unstructured":"Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 1995;86: 2041-2050.","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041"},{"key":"2020021223230224600_","doi-asserted-by":"crossref","unstructured":"Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood. 1996;87: 2195-2204.","DOI":"10.1182\/blood.V87.6.2195.bloodjournal8762195"},{"key":"2020021223230224600_REF8","doi-asserted-by":"crossref","unstructured":"Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15: 433-444.","DOI":"10.1200\/JCO.1997.15.2.433"},{"key":"2020021223230224600_REF9","doi-asserted-by":"crossref","unstructured":"Verdonck LF, Petersen EJ, Lokhorst HM, et al. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Bone Marrow Transplant. 1998;22: 1057-1063.","DOI":"10.1038\/sj.bmt.1701496"},{"key":"2020021223230224600_REF10","doi-asserted-by":"crossref","unstructured":"Collins RH Jr, Goldstein S, Giralt S, et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant. 2000;26: 511-516.","DOI":"10.1038\/sj.bmt.1702555"},{"key":"2020021223230224600_REF11","doi-asserted-by":"crossref","unstructured":"Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood. 2002;100: 1935-1947.","DOI":"10.1182\/blood-2002-02-0350"},{"key":"2020021223230224600_REF12","doi-asserted-by":"crossref","unstructured":"Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295: 2097-2100.","DOI":"10.1126\/science.1068440"},{"key":"2020021223230224600_REF13","doi-asserted-by":"crossref","unstructured":"Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94: 333-339.","DOI":"10.1182\/blood.V94.1.333.413a31_333_339"},{"key":"2020021223230224600_","doi-asserted-by":"crossref","unstructured":"Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102: 814-819.","DOI":"10.1182\/blood-2003-01-0091"},{"key":"2020021223230224600_REF15","doi-asserted-by":"crossref","unstructured":"Leung W, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol. 2004;172: 644-650.","DOI":"10.4049\/jimmunol.172.1.644"},{"key":"2020021223230224600_","doi-asserted-by":"crossref","unstructured":"Frohn C, Brand JM, Luhm J. NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol. 2003;24: 8-9.","DOI":"10.1016\/S1471-4906(02)00002-9"},{"key":"2020021223230224600_REF17","doi-asserted-by":"crossref","unstructured":"Caligiuri MA, Velardi A, Scheinberg DA, Borrello IM. Immunotherapeutic approaches for hematologic malignancies. Hematology (Am Soc Hematol Educ Program). 2004; 337-353.","DOI":"10.1182\/asheducation-2004.1.337"},{"key":"2020021223230224600_REF18","doi-asserted-by":"crossref","unstructured":"Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3: 35-45.","DOI":"10.1038\/nrc971"},{"key":"2020021223230224600_","doi-asserted-by":"crossref","unstructured":"Cooper LJ, Topp MS, Serrano LM, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood. 2003;101: 1637-1644.","DOI":"10.1182\/blood-2002-07-1989"},{"key":"2020021223230224600_","doi-asserted-by":"crossref","unstructured":"Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes costimulated by CD80 and interleukin-15. Nat Med. 2003;9: 279-286.","DOI":"10.1038\/nm827"},{"key":"2020021223230224600_REF21","doi-asserted-by":"crossref","unstructured":"Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Campana D. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004;18: 676-684.","DOI":"10.1038\/sj.leu.2403302"},{"key":"2020021223230224600_","doi-asserted-by":"crossref","unstructured":"Ito C, Kumagai M, Manabe A, et al. Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis. Blood. 1999;93: 315-320.","DOI":"10.1182\/blood.V93.1.315"},{"key":"2020021223230224600_REF23","doi-asserted-by":"crossref","unstructured":"Srivannaboon K, Shanafelt AB, Todisco E, et al. Interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells. Blood. 2001;97: 752-758.","DOI":"10.1182\/blood.V97.3.752"},{"key":"2020021223230224600_REF24","unstructured":"Robertson MJ, Cameron C, Lazo S, Cochran KJ, Voss SD, Ritz J. Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals. Nat Immunol. 1996;15: 213-226."},{"key":"2020021223230224600_REF25","doi-asserted-by":"crossref","unstructured":"Maus MV, Thomas AK, Leonard DG, et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol. 2002;20: 143-148.","DOI":"10.1038\/nbt0202-143"},{"key":"2020021223230224600_REF26","doi-asserted-by":"crossref","unstructured":"Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol. 1998;190: 167-172.","DOI":"10.1006\/cimm.1998.1396"},{"key":"2020021223230224600_REF27","doi-asserted-by":"crossref","unstructured":"Carson WE, Fehniger TA, Haldar S, et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival J Clin Invest. 1997;99: 937-943.","DOI":"10.1172\/JCI119258"},{"key":"2020021223230224600_","doi-asserted-by":"crossref","unstructured":"Cooper MA, Bush JE, Fehniger TA, et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood. 2002;100: 3633-3638.","DOI":"10.1182\/blood-2001-12-0293"},{"key":"2020021223230224600_","doi-asserted-by":"crossref","unstructured":"Fehniger TA, Caligiuri MA. Ontogeny and expansion of human natural killer cells: clinical implications. Int Rev Immunol. 2001;20: 503-534.","DOI":"10.3109\/08830180109054417"},{"key":"2020021223230224600_REF30","doi-asserted-by":"crossref","unstructured":"Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res2003;90: 127-156.","DOI":"10.1016\/S0065-230X(03)90004-2"},{"key":"2020021223230224600_REF31","doi-asserted-by":"crossref","unstructured":"Musso T, Calosso L, Zucca M, et al. Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15. Blood. 1999;93: 3531-3539.","DOI":"10.1182\/blood.V93.10.3531.410k32_3531_3539"},{"key":"2020021223230224600_","doi-asserted-by":"crossref","unstructured":"Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 in trans to neighboring cells. Immunity. 2002;17: 537-547.","DOI":"10.1016\/S1074-7613(02)00429-6"},{"key":"2020021223230224600_","doi-asserted-by":"crossref","unstructured":"Koka R, Burkett P, Chien M, Chai S, Boone DL, Ma A. Cutting edge: murine dendritic cells require IL-15R alpha to prime NK cells. J Immunol. 2004;173: 3594-3598.","DOI":"10.4049\/jimmunol.173.6.3594"},{"key":"2020021223230224600_","doi-asserted-by":"crossref","unstructured":"Burkett PR, Koka R, Chien M, Chai S, Boone DL, Ma A. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J Exp Med. 2004;200: 825-834.","DOI":"10.1084\/jem.20041389"},{"key":"2020021223230224600_REF35","doi-asserted-by":"crossref","unstructured":"Kobayashi H, Dubois S, Sato N, et al. The role of trans-cellular IL-15-presentation in the activation of NK-mediated killing, which leads to enhanced tumor immune surveillance. Blood. 2005;105: 721-727.","DOI":"10.1182\/blood-2003-12-4187"},{"key":"2020021223230224600_REF36","doi-asserted-by":"crossref","unstructured":"Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 2004;23: 255-259.","DOI":"10.1038\/sj.emboj.7600019"},{"key":"2020021223230224600_REF37","doi-asserted-by":"crossref","unstructured":"Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat Immunol. 2003;4: 557-564.","DOI":"10.1038\/ni929"},{"key":"2020021223230224600_REF38","doi-asserted-by":"crossref","unstructured":"Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric receptor genes in human T cells. J Immunol Methods. 2001;248: 67-76.","DOI":"10.1016\/S0022-1759(00)00343-4"},{"key":"2020021223230224600_","doi-asserted-by":"crossref","unstructured":"Hombach A, Wieczarkowiecz A, Marquardt T, et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28\/CD3 zeta signaling receptor molecule. J Immunol. 2001;167: 6123-6131.","DOI":"10.4049\/jimmunol.167.11.6123"},{"key":"2020021223230224600_","doi-asserted-by":"crossref","unstructured":"Geiger TL, Nguyen P, Leitenberg D, Flavell RA. Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood. 2001;98: 2364-2371.","DOI":"10.1182\/blood.V98.8.2364"},{"key":"2020021223230224600_","doi-asserted-by":"crossref","unstructured":"Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor. Nat Biotechnol. 2002;20: 70-75.","DOI":"10.1038\/nbt0102-70"},{"key":"2020021223230224600_","doi-asserted-by":"crossref","unstructured":"Haynes NM, Trapani JA, Teng MW, et al. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol. 2002;169: 5780-5786.","DOI":"10.4049\/jimmunol.169.10.5780"},{"key":"2020021223230224600_REF43","doi-asserted-by":"crossref","unstructured":"Haynes NM, Trapani JA, Teng MW, et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood. 2002;100: 3155-3163.","DOI":"10.1182\/blood-2002-04-1041"},{"key":"2020021223230224600_REF44","doi-asserted-by":"crossref","unstructured":"Lang S, Vujanovic NL, Wollenberg B, Whiteside TL. Absence of B7.1-CD28\/CTLA-4-mediated co-stimulation in human NK cells. Eur J Immunol. 1998;28: 780-786.","DOI":"10.1002\/(SICI)1521-4141(199803)28:03<780::AID-IMMU780>3.0.CO;2-8"},{"key":"2020021223230224600_REF45","doi-asserted-by":"crossref","unstructured":"Goodier MR, Londei M. CD28 is not directly involved in the response of human CD3- CD56+ natural killer cells to lipopolysaccharide: a role for T cells. Immunology. 2004;111: 384-390.","DOI":"10.1111\/j.0019-2805.2004.01834.x"},{"key":"2020021223230224600_REF46","doi-asserted-by":"crossref","unstructured":"Pan PY, Gu P, Li Q, Xu D, Weber K, Chen SH. Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation. J Immunol. 2004;172: 4779-4789.","DOI":"10.4049\/jimmunol.172.8.4779"},{"key":"2020021223230224600_REF47","doi-asserted-by":"crossref","unstructured":"Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002;1: 133-143.","DOI":"10.1016\/S1535-6108(02)00032-6"},{"key":"2020021223230224600_REF48","doi-asserted-by":"crossref","unstructured":"Roberts MR, Cooke KS, Tran AC, et al. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains. J Immunol. 1998;161: 375-384.","DOI":"10.4049\/jimmunol.161.1.375"},{"key":"2020021223230224600_","doi-asserted-by":"crossref","unstructured":"Nagashima S, Mailliard R, Kashii Y, et al. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood. 1998;91: 3850-3861.","DOI":"10.1182\/blood.V91.10.3850"},{"key":"2020021223230224600_","doi-asserted-by":"crossref","unstructured":"Uherek C, Tonn T, Uherek B, et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood. 2002;100: 1265-1273.","DOI":"10.1182\/blood.V100.4.1265.h81602001265_1265_1273"},{"key":"2020021223230224600_","doi-asserted-by":"crossref","unstructured":"Schirrmann T, Pecher G. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo. Cancer Gene Ther. 2002;9: 390-398.","DOI":"10.1038\/sj.cgt.7700453"},{"key":"2020021223230224600_","doi-asserted-by":"crossref","unstructured":"Tam YK, Martinson JA, Doligosa K, Klingemann HG. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy. 2003;5: 259-272.","DOI":"10.1080\/14653240310001523"},{"key":"2020021223230224600_","doi-asserted-by":"crossref","unstructured":"Maasho K, Marusina A, Reynolds NM, Coligan JE, Borrego F. Efficient gene transfer into the human natural killer cell line, NKL, using the Amaxa nucleofection system. J Immunol Methods. 2004;284: 133-140.","DOI":"10.1016\/j.jim.2003.10.010"},{"key":"2020021223230224600_REF54","unstructured":"Zhang J, Sun R, Wei H, Zhang J, Tian Z. Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy. Haematologica. 2004;89: 338-347."},{"key":"2020021223230224600_REF55","doi-asserted-by":"crossref","unstructured":"Trompeter HI, Weinhold S, Thiel C, Wernet P, Uhrberg M. Rapid and highly efficient gene transfer into natural killer cells by nucleofection. J Immunol Methods. 2003;274: 245-256.","DOI":"10.1016\/S0022-1759(02)00431-3"},{"key":"2020021223230224600_REF56","doi-asserted-by":"crossref","unstructured":"Schroers R, Hildebrandt Y, Hasenkamp J, et al. Gene transfer into human T lymphocytes and natural killer cells by Ad5\/F35 chimeric adenoviral vectors. Exp Hematol. 2004;32: 536-546.","DOI":"10.1016\/j.exphem.2004.03.010"},{"key":"2020021223230224600_REF57","doi-asserted-by":"crossref","unstructured":"Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Seehra J, London L, Perussia B. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med. 1984;160: 1147-1169.","DOI":"10.1084\/jem.160.4.1147"},{"key":"2020021223230224600_REF58","doi-asserted-by":"crossref","unstructured":"Naume B, Gately M, Espevik T. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells. J Immunol. 1992;148: 2429-2436.","DOI":"10.4049\/jimmunol.148.8.2429"},{"key":"2020021223230224600_REF59","unstructured":"Perussia B, Ramoni C, Anegon I, Cuturi MC, Faust J, Trinchieri G. Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines. Nat Immun Cell Growth Regul. 1987;6: 171-188."},{"key":"2020021223230224600_REF60","doi-asserted-by":"crossref","unstructured":"Miller JS, Oelkers S, Verfaillie C, McGlave P. Role of monocytes in the expansion of human activated natural killer cells. Blood. 1992;80: 2221-2229.","DOI":"10.1182\/blood.V80.9.2221.2221"},{"key":"2020021223230224600_REF61","doi-asserted-by":"crossref","unstructured":"Harada H, Saijo K, Watanabe S, et al. Selective expansion of human natural killer cells from peripheral blood mononuclear cells by the cell line, HFWT. Jpn J Cancer Res. 2002;93: 313-319.","DOI":"10.1111\/j.1349-7006.2002.tb02174.x"},{"key":"2020021223230224600_REF62","doi-asserted-by":"crossref","unstructured":"Chiorean EG, Miller JS. The biology of natural killer cells and implications for therapy of human disease. J Hematother Stem Cell Res. 2001;10: 451-463.","DOI":"10.1089\/15258160152509073"},{"key":"2020021223230224600_REF63","unstructured":"Billingham RE, Brent L, Medawar PB. Quantitative studies on tissue transplantation immunity, II: the origin, strength and duration of actively and adoptively acquired immunity. Proceed R Soc. 1954;143: 58-80."},{"key":"2020021223230224600_REF64","doi-asserted-by":"crossref","unstructured":"Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333: 1038-1044.","DOI":"10.1056\/NEJM199510193331603"},{"key":"2020021223230224600_REF65","doi-asserted-by":"crossref","unstructured":"Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345: 9-13.","DOI":"10.1016\/S0140-6736(95)91150-2"},{"key":"2020021223230224600_REF66","doi-asserted-by":"crossref","unstructured":"Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in cancer patients. Blood. 2005;105: 3051-3057.","DOI":"10.1182\/blood-2004-07-2974"},{"key":"2020021223230224600_REF67","doi-asserted-by":"crossref","unstructured":"Baum C, Dullmann J, Li Z, et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood. 2003;101: 2099-2114.","DOI":"10.1182\/blood-2002-07-2314"},{"key":"2020021223230224600_REF68","doi-asserted-by":"crossref","unstructured":"Marktel S, Magnani Z, Ciceri F, et al. Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood. 2003;101: 1290-1298.","DOI":"10.1182\/blood-2002-08-2351"},{"key":"2020021223230224600_REF69","doi-asserted-by":"crossref","unstructured":"Campana D, Behm FG. Immunophenotyping of leukemia. J Immunol Methods. 2000;243: 59-75.","DOI":"10.1016\/S0022-1759(00)00228-3"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/1\/376\/1710864\/zh801305000376.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/1\/376\/1710864\/zh801305000376.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T19:41:08Z","timestamp":1706038868000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/106\/1\/376\/103178\/Genetic-modification-of-primary-natural-killer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,1]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,7,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-12-4797","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,1]]}}}